Published in Ann Oncol on August 16, 2012
Clinical update on cancer: molecular oncology of head and neck cancer. Cell Death Dis (2014) 1.22
Cetuximab: its unique place in head and neck cancer treatment. Biologics (2013) 1.01
Promising systemic immunotherapies in head and neck squamous cell carcinoma. Oral Oncol (2013) 0.93
Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehensive European cancer institution. PLoS One (2014) 0.92
Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales. Br J Pharmacol (2013) 0.92
Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer. Oncoscience (2014) 0.91
Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumors. Am J Transl Res (2015) 0.87
Upregulated interleukin-6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma. Mol Oncol (2015) 0.85
Cancer therapy and cardiovascular risk: focus on bevacizumab. Cancer Manag Res (2015) 0.84
Immune biomarkers of anti-EGFR monoclonal antibody therapy. Ann Oncol (2014) 0.84
Zirconium-89 labeled antibodies: a new tool for molecular imaging in cancer patients. Biomed Res Int (2014) 0.84
MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells. Cancer Res (2015) 0.83
Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer. Cancer (2013) 0.83
Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma. Head Neck (2015) 0.82
Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC). Cancers (Basel) (2016) 0.81
Recent Progress in Therapeutic Treatments and Screening Strategies for the Prevention and Treatment of HPV-Associated Head and Neck Cancer. Viruses (2015) 0.79
The Proton-Sensing G-Protein Coupled Receptor GPR4 Promotes Angiogenesis in Head and Neck Cancer. PLoS One (2016) 0.78
EGFR Regulates the Development and Microarchitecture of Intratumoral Angiogenic Vasculature Capable of Sustaining Cancer Cell Intravasation. Neoplasia (2015) 0.78
Time-dependent pretreatment with bevacuzimab increases tumor specific uptake of cetuximab in preclinical oral cavity cancer studies. Cancer Biol Ther (2015) 0.77
Predictive biomarkers to anti-VEGF therapy: progress toward an elusive goal. Clin Cancer Res (2013) 0.77
Immunotherapy for Head and Neck Squamous Cell Carcinoma. Curr Oral Health Rep (2016) 0.76
Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget (2016) 0.76
Preclinical Activity of the Vascular Disrupting Agent OXi4503 against Head and Neck Cancer. Cancers (Basel) (2016) 0.75
A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma. Oral Oncol (2015) 0.75
Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines. J Cancer Res Clin Oncol (2016) 0.75
Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma. Oncotarget (2016) 0.75
Bevacizumab plus cisplatin and helical tomotherapy in treatment of locally advanced nasopharyngeal carcinoma. Onco Targets Ther (2015) 0.75
Combining antiangiogenic therapy and radiation in nasopharyngeal carcinoma. Saudi Med J (2015) 0.75
Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients. J Immunother Cancer (2016) 0.75
Effect of selective small molecule inhibitors on MMP-9 and VEGFR-1 expression in p16-positive and -negative squamous cell carcinoma. Oncol Lett (2017) 0.75
RGD-K5 PET/CT in patients with advanced head and neck cancer treated with concurrent chemoradiotherapy: Results from a pilot study. Eur J Nucl Med Mol Imaging (2016) 0.75
Dramatic response of CTNNB1 and VEGFR-2 mutant temporal bone squamous cell carcinoma to bevacizumab in combination with pemetrexed. Oncotarget (2017) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol (2008) 15.17
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59
Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med (2008) 11.86
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med (2009) 11.63
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell (2005) 9.18
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 9.05
Head and neck cancer. Lancet (2008) 6.33
A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol (2008) 5.56
Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev (2005) 4.65
Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res (2008) 4.30
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol (2004) 3.67
Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol (2007) 2.77
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol (2009) 2.45
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res (2003) 2.26
Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol (1992) 2.19
The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res (2007) 2.13
Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Clin Cancer Res (2009) 1.85
A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol (1992) 1.84
ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res (2002) 1.67
Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-antisense therapy. Clin Cancer Res (2002) 1.55
Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol (2006) 1.54
HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clin Cancer Res (2010) 1.50
Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer (2004) 1.43
Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA (2007) 1.41
Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis. Am J Pathol (2003) 1.39
Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model. Br J Cancer (2008) 1.33
Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies. Int J Radiat Oncol Biol Phys (2004) 1.21
Bevacizumab: current indications and future development for management of solid tumors. Expert Opin Biol Ther (2009) 1.09
Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol (2011) 1.04
Immunohistochemical analysis of phosphotyrosine signal transducer and activator of transcription 3 and epidermal growth factor receptor autocrine signaling pathways in head and neck cancers and metastatic lymph nodes. Clin Cancer Res (2008) 1.00
Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma. Laryngoscope (2007) 0.99
Augmentation of radiation response with the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys (2006) 0.94
Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group. Cancer (2009) 0.94
Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies. Invest New Drugs (2011) 0.81
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature (1994) 21.59
Genome cross-referencing and XREFdb: implications for the identification and analysis of genes mutated in human disease. Nat Genet (1997) 10.14
Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med (1995) 8.51
The genome of the natural genetic engineer Agrobacterium tumefaciens C58. Science (2001) 6.90
REST: a mammalian silencer protein that restricts sodium channel gene expression to neurons. Cell (1995) 6.43
Radiation hybrid mapping: a somatic cell genetic method for constructing high-resolution maps of mammalian chromosomes. Science (1990) 5.35
A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med (1992) 5.10
HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene (2012) 4.30
A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators. N Engl J Med (2000) 4.14
Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene (2008) 4.13
Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med (1997) 4.10
Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci U S A (2000) 4.08
Specific and nonspecific NK cell activation during virus infection. Nat Immunol (2001) 4.02
Imaging membrane protein helical wheels. J Magn Reson (2000) 3.80
Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem (2000) 3.74
"Fluorescent timer": protein that changes color with time. Science (2000) 3.42
Structural basis of the redox switch in the OxyR transcription factor. Cell (2001) 3.32
Inhibition of human immunodeficiency virus gene amplification by heparin. J Clin Microbiol (1991) 3.32
Structure of the transmembrane region of the M2 protein H(+) channel. Protein Sci (2001) 3.31
Identification of sequences in a yeast histone promoter involved in periodic transcription. Cell (1986) 3.22
Weighted-ensemble Brownian dynamics simulations for protein association reactions. Biophys J (1996) 2.87
SCL and LMO1 alter thymocyte differentiation: inhibition of E2A-HEB function and pre-T alpha chain expression. Nat Immunol (2000) 2.87
Predicting protein diffusion coefficients. Proc Natl Acad Sci U S A (1993) 2.87
Search for a resonance decaying into WZ boson pairs in pp collisions. Phys Rev Lett (2010) 2.83
Kinetics of expression of multiply spliced RNA in early human immunodeficiency virus type 1 infection of lymphocytes and monocytes. Proc Natl Acad Sci U S A (1991) 2.81
Genomic organization of Borna disease virus. Proc Natl Acad Sci U S A (1994) 2.74
Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res (1997) 2.72
Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res (1999) 2.71
Programmable matter by folding. Proc Natl Acad Sci U S A (2010) 2.65
Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol (1983) 2.64
Efficient expression of the Saccharomyces cerevisiae PGK gene depends on an upstream activation sequence but does not require TATA sequences. Mol Cell Biol (1986) 2.63
Identification of c-myc responsive genes using rat cDNA microarray. Cancer Res (2000) 2.62
AN APPROXIMATE CELL MODEL FOR LIQUID HYDROGEN, I. Proc Natl Acad Sci U S A (1962) 2.59
Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res (2000) 2.56
Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J (2001) 2.55
Cerberus is a head-inducing secreted factor expressed in the anterior endoderm of Spemann's organizer. Nature (1996) 2.54
Interorganelle signaling is a determinant of longevity in Saccharomyces cerevisiae. Genetics (1999) 2.50
Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood (2000) 2.42
Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res (1998) 2.38
DNA looping generated by DNA bending protein IHF and the two domains of lambda integrase. Science (1989) 2.34
Trends in diet, nutritional status, and diet-related noncommunicable diseases in China and India: the economic costs of the nutrition transition. Nutr Rev (2001) 2.33
Regulation of the mating pheromone and invasive growth responses in yeast by two MAP kinase substrates. Curr Biol (1997) 2.32
PRMT1 is the predominant type I protein arginine methyltransferase in mammalian cells. J Biol Chem (2000) 2.26
Estrogen inhibits the vascular injury response in estrogen receptor alpha-deficient mice. Nat Med (1997) 2.24
STAT signaling in head and neck cancer. Oncogene (2000) 2.19
Induction of gamma interferon production in human alveolar macrophages by Mycobacterium tuberculosis. Infect Immun (1997) 2.16
Function of the c-Myc oncogenic transcription factor. Exp Cell Res (1999) 2.11
Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer. Ann Oncol (2003) 2.09
Hydrodynamic steering effects in protein association. Proc Natl Acad Sci U S A (1994) 2.09
Cycloplegic refractions in healthy children aged 1 through 48 months. Arch Ophthalmol (2001) 2.07
Structure and expression of a smooth muscle cell-specific gene, SM22 alpha. J Biol Chem (1995) 2.05
Idealized versus realized overall treatment times. Int J Radiat Oncol Biol Phys (1994) 2.02
Cinnamon zeylanicum bark extract and powder mediated green synthesis of nano-crystalline silver particles and its bactericidal activity. Colloids Surf B Biointerfaces (2009) 2.01
Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. J Virol (1999) 1.97
Protein methylation. Science (1971) 1.95
Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther (1999) 1.94
Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med (1980) 1.91
Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer (2005) 1.86
Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med (1982) 1.85
The prevalence of and risk factors for erosive oesophagitis and non-erosive reflux disease: a nationwide multicentre prospective study in Korea. Aliment Pharmacol Ther (2007) 1.85
Molecular cloning of translocations involving chromosome 15 and the immunoglobulin C alpha gene from chromosome 12 in two murine plasmacytomas. Proc Natl Acad Sci U S A (1982) 1.84
Zuotin, a ribosome-associated DnaJ molecular chaperone. EMBO J (1998) 1.84
Inhibition of the phosphatidylinositol 3-kinase pathway contributes to HT29 and Caco-2 intestinal cell differentiation. Gastroenterology (2001) 1.84
The natural history of breast cancer patients with brain metastases. Cancer (1979) 1.82
Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res (1986) 1.82
The RNA polymerase II general transcription factors: past, present, and future. Cold Spring Harb Symp Quant Biol (1998) 1.82
Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth. Nature (1998) 1.82
Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood (1983) 1.80
Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer (2003) 1.80
Indication for endoscopic mucosal resection in early signet ring cell gastric cancer. Ann Surg Oncol (2007) 1.77
Epidemiological studies on hemorrhagic fever with renal syndrome in China. J Infect Dis (1986) 1.77
Fibrillar collagen specifically regulates human vascular smooth muscle cell genes involved in cellular responses and the pericellular matrix environment. Circ Res (2001) 1.76
Solution structure of the C-terminal core domain of human TFIIB: similarity to cyclin A and interaction with TATA-binding protein. Cell (1995) 1.75
Protein methylase I. Purification and properties of the enzyme. J Biol Chem (1968) 1.75
Synthesis of a muscarinic receptor antagonist via a diastereoselective Michael reaction, selective deoxyfluorination and aromatic metal-halogen exchange reaction. J Org Chem (2001) 1.75
3D time-resolved MR angiography (MRA) of the carotid arteries with time-resolved imaging with stochastic trajectories: comparison with 3D contrast-enhanced Bolus-Chase MRA and 3D time-of-flight MRA. AJNR Am J Neuroradiol (2008) 1.74
Analysis of SM22alpha-deficient mice reveals unanticipated insights into smooth muscle cell differentiation and function. Mol Cell Biol (2001) 1.74
Measuring the full economic costs of diet, physical activity and obesity-related chronic diseases. Obes Rev (2006) 1.74
Postoperative chemoradiotherapy for gastric cancer. Ann Oncol (2003) 1.73
Longitudinal versus cross-sectional evaluations of leukocyte telomere length dynamics: age-dependent telomere shortening is the rule. J Gerontol A Biol Sci Med Sci (2011) 1.72
Molecular mechanisms of Spemann's organizer formation: conserved growth factor synergy between Xenopus and mouse. Genes Dev (1995) 1.71
The epidemiology of total knee replacement in South Korea: national registry data. Rheumatology (Oxford) (2008) 1.71
A new atmospherically relevant oxidant of sulphur dioxide. Nature (2012) 1.71
Protein methylation: chemical, enzymological, and biological significance. Adv Enzymol Relat Areas Mol Biol (1975) 1.68
The transcriptional activity of cAMP response element-binding protein-binding protein is modulated by the latency associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. J Biol Chem (2001) 1.67
Analysis of gene expression in a complex differentiation hierarchy by global amplification of cDNA from single cells. Curr Biol (1995) 1.67
Silicone oil adhesion to intraocular lenses: an experimental study comparing various biomaterials. J Cataract Refract Surg (1997) 1.67
Analysis of a recombination hotspot for gene conversion occurring at the HIS2 gene of Saccharomyces cerevisiae. Genetics (1994) 1.67
Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial. Br J Cancer (2013) 1.65
Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Cancer Res (1995) 1.64
Clipping vs coiling of posterior communicating artery aneurysms with third nerve palsy. Neurology (2006) 1.64
Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proc Natl Acad Sci U S A (1999) 1.63
Detection by scanning electron microscopy of a distinctive esophageal surface cell at the junction of squamous and Barrett's epithelium. Dig Dis Sci (1993) 1.63
Dietary adherence and weight loss success among overweight women: results from the A TO Z weight loss study. Int J Obes (Lond) (2008) 1.63
Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res (1979) 1.62
Early and delayed clinical cardiotoxicity of doxorubicin. Cancer (1985) 1.61
Etiology and prevention of substance use among Asian American youth. Prev Sci (2001) 1.59